A Phase I/II Trial of Pembrolizumab (MK-3475) and Poly-ICLC in Patients With Metastatic Mismatch Repair-proficient (MRP) Colon Cancer

Trial Profile

A Phase I/II Trial of Pembrolizumab (MK-3475) and Poly-ICLC in Patients With Metastatic Mismatch Repair-proficient (MRP) Colon Cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Poly ICLC (Primary)
  • Indications Colon cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Nov 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
    • 25 Nov 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
    • 19 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top